ORIC PHARMACEUTICALS INC. - COMMON STOCK

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

18 2 2025 16:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 2 2025 16:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

27 1 2025 16:15:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

13 1 2025 08:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

13 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1 2025 16:15:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 1 2025 16:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

25 11 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

12 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

04 11 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

23 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

09 10 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 10 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 9 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

26 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

12 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

05 8 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

16 7 2024 16:59:15 提供 Nasdaq GlobeNewswire